Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
Open accessThe DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.
Abstract
Background Genexol-PM is a novel Cremophor EL (CrEL)-free polymeric micelle formulation of paclitaxel (Taxol). This multicenter phase II study was designed to evaluate the efficacy and safety of the combination of Genexol-PM and cisplatin for the treatment of advanced non-small-cell lung cancer (NSCLC).Patients and methods Patients with advanced NSCLC received Genexol-PM 230 mg/m(2) and cisplatin 60 mg/m(2) on day 1 of a 3-week cycle as first-line therapy. Intrapatient dose escalation of Genexol-PM to 300 mg/m(2) was carried out from the second cycle if the prespecified toxic effects were not observed after the first cycle.Results Sixty-nine patients were enrolled in this study. Overall response rate was 37.7%. The median time to progression was 5.8 months and the median survival period was 21.7 months. The major non-hematologic toxic effects included grade 3 peripheral sensory neuropathy (13.0%) and grade 3/4 arthralgia (7.3%). Four patients (5.8%) experienced grade 3/4 hypersensitivity reactions. The major hematological toxic effects were grade 3/4 neutropenia (29.0% and 17.4%, respectively).Conclusion Genexol-PM plus cisplatin combination chemotherapy showed significant antitumor activity. The use of CrEL-free, polymeric micelle formulation of paclitaxel allowed administration of higher doses of paclitaxel compared with the CrEL-based formulation without significant increased toxicity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although Genexol® PM has shown some hypersensitivity reaction in the clinic, probably due to the PEG, this is not nearly as much of a concern as for Taxol® which contains Cremophor EL [301].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [301]
In the citing paper
“The overall response rate was 37.7% and the median survival period was 21.7 months, which indicated significant improvements compared to previous clinical trials conducted with Taxol® 175–200 mg/m2 and cisplatin 75–80 mg/m2 [301].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [301]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Self-citationIn vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Self-citation
Cited by
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 1,334
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Imaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery
Chan, J. M., Zhang, L., Yuet, K. P., Liao, G., Rhee, J.-W., Langer, R., & Farokhzad, O. C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.013 · Cited by 702
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Cell membrane-camouflaged nanoparticles for drug delivery
Luk, B. T., & Zhang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.019 · Cited by 610
Muthu, M. S., Leong, D. T., Mei, L., & Feng, S.-S. (2014) · Theranostics · doi:10.7150/thno.8698 · Cited by 603
Nanooncology: The future of cancer diagnosis and therapy
Thakor, A. S., & Gambhir, S. S. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21199 · Cited by 588
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Lu, Y., & Park, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.042 · Cited by 572
Self-citationPolymeric micelles drug delivery system in oncology
Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.012 · Cited by 570
Kim, S., Shi, Y., Kim, J. Y., Park, K., & Cheng, J.-X. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903380446 · Cited by 549
Self-citationTalelli, M., Barz, M., Rijcken, C. J. F., Kiessling, F., Hennink, W. E., & Lammers, T. (2015) · Nano Today · doi:10.1016/j.nantod.2015.01.005 · Cited by 506
Polymeric nanoparticles: the future of nanomedicine
Banik, B. L., Fattahi, P., & Brown, J. L. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1364 · Cited by 485
Gene therapy and DNA delivery systems
Ibraheem, D., Elaissari, A., & Fessi, H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.11.041 · Cited by 454
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Polymeric micelles: nanocarriers for cancer-targeted drug delivery
Zhang, Y., Huang, Y., & Li, S. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0113-z · Cited by 367
“advanced non-small-cell lung cancer (15).”
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
Polymeric nanostructured materials for biomedical applications
Tang, Z., He, C., Tian, H., Ding, J., Hsiao, B. S., Chu, B., & Chen, X. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.05.005 · Cited by 363
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes
Gaucher, G., Marchessault, R. H., & Leroux, J.-C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.012 · Cited by 315
Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy
Gindy, M. E., & Prud'homme, R. K. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902932908 · Cited by 298
Micelles structure development as a strategy to improve smart cancer therapy
Hanafy, N., El-Kemary, M., & Leporatti, S. (2018) · Cancers · doi:10.3390/cancers10070238 · Cited by 287
“In clinical trials, NK911 and SP1049C [104] and NK105 and NC6004 are currently passed to Phases I and II [106,107].”
BackgroundTargeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles
Rodzinski, A., Guduru, R., Liang, P., Hadjikhani, A., Stewart, T., Stimphil, E., Runowicz, C., Cote, R., Altman, N., Datar, R., et al. (2016) · Scientific Reports · doi:10.1038/srep20867 · Cited by 271
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Werner, M. E., Cummings, N. D., Sethi, M., Wang, E. C., Sukumar, R., Moore, D. T., & Wang, A. Z. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.009 · Cited by 267
Update on taxane development: new analogs and new formulations
Tkaczuk, K., & Yared, J. (2012) · Drug Design, Development and Therapy · doi:10.2147/dddt.s28997 · Cited by 247
Current Advances in Polymer-Based Nanotheranostics for Cancer Treatment and Diagnosis
Luk, B. T., & Zhang, L. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am5036225 · Cited by 239
Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs
Gothwal, A., Khan, I., & Gupta, U. (2016) · Pharmaceutical Research · doi:10.1007/s11095-015-1784-1 · Cited by 233
Advances of Cancer Therapy by Nanotechnology
Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.1.1 · Cited by 230
Yokoyama, M. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903436479 · Cited by 224
Shi, Y., van der Meel, R., Theek, B., Oude Blenke, E., Pieters, E. H. E., Fens, M. H. A. M., Ehling, J., Schiffelers, R. M., Storm, G., van Nostrum, C. F., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b00929 · Cited by 214
Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients
Chariou, P. L., Ortega-Rivera, O. A., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c00173 · Cited by 212
Approved Nanomedicine against Diseases
Jia, Y., Jiang, Y., He, Y., Zhang, W., Zou, J., Magar, K. T., Boucetta, H., Teng, C., & He, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030774 · Cited by 203
Hu, C.-M. J., Fang, R. H., Luk, B. T., & Zhang, L. (2014) · Nanoscale · doi:10.1039/c3nr05444f · Cited by 201
Nanoparticle‐Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges
Babu, A., Templeton, A. K., Munshi, A., & Ramesh, R. (2013) · Journal of Nanomaterials · doi:10.1155/2013/863951 · Cited by 199
Solubilization techniques used for poorly water-soluble drugs
Xie, B., Liu, Y., Li, X., Yang, P., & He, W. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.027 · Cited by 196
Advances in Lung Cancer Treatment Using Nanomedicines
Sharma, A., Shambhwani, D., Pandey, S., Singh, J., Lalhlenmawia, H., Kumarasamy, M., Singh, S. K., Chellappan, D. K., Gupta, G., Prasher, P., et al. (2023) · ACS Omega · doi:10.1021/acsomega.2c04078 · Cited by 188
Ahn, H. K., Jung, M., Sym, S. J., Shin, D. B., Kang, S. M., Kyung, S. Y., Park, J.-W., Jeong, S. H., & Cho, E. K. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2498-5 · Cited by 183
Development of polymeric micelles for targeting intractable cancers
Nishiyama, N., Matsumura, Y., & Kataoka, K. (2016) · Cancer Science · doi:10.1111/cas.12960 · Cited by 180
Patel, J. D., Hensing, T. A., Rademaker, A., Hart, E. M., Blum, M. G., Milton, D. T., & Bonomi, P. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8181 · Cited by 178
Nanotechnology in the diagnosis and treatment of lung cancer
Cryer, A. M., & Thorley, A. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.010 · Cited by 172
Potential applications of engineered nanoparticles in medicine and biology: an update
Rudramurthy, G. R., & Swamy, M. K. (2018) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-018-1600-6 · Cited by 171
Clinical Developments in Nanotechnology for Cancer Therapy
Heidel, J. D., & Davis, M. E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0178-7 · Cited by 170
Nanocarriers for intravenous injection—The long hard road to the market
Wacker, M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.08.079 · Cited by 170
Lee, S.-W., Yun, M.-H., Jeong, S. W., In, C.-H., Kim, J.-Y., Seo, M.-H., Pai, C.-M., & Kim, S.-O. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.012 · Cited by 169
Self-citationNanotechnology for the delivery of phytochemicals in cancer therapy
Xie, J., Yang, Z., Zhou, C., Zhu, J., Lee, R. J., & Teng, L. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.04.002 · Cited by 168
Clinical application of polymeric micelles for the treatment of cancer
Varela-Moreira, A., Shi, Y., Fens, M. H. A. M., Lammers, T., Hennink, W. E., & Schiffelers, R. M. (2017) · Materials Chemistry Frontiers · doi:10.1039/c6qm00289g · Cited by 168
Polymers in Drug Delivery—State of the Art and Future Trends
Grund, S., Bauer, M., & Fischer, D. (2011) · Advanced Engineering Materials · doi:10.1002/adem.201080088 · Cited by 165
Targeted Nanotechnology in Glioblastoma Multiforme
Glaser, T., Han, I., Wu, L., & Zeng, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00166 · Cited by 164
Lim, W., Tan, E. H., Toh, C., Hee, S. W., Leong, S. S., Ang, P., Wong, N. S., & Chowbay, B. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp315 · Cited by 162
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer
Woodman, C., Vundu, G., George, A., & Wilson, C. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.009 · Cited by 161
Injectable formulations of poly(lactic acid) and its copolymers in clinical use
Jain, A., Kunduru, K. R., Basu, A., Mizrahi, B., Domb, A. J., & Khan, W. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.002 · Cited by 160
Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel
He, H., Chen, S., Zhou, J., Dou, Y., Song, L., Che, L., Zhou, X. W., Chen, X., Jia, Y., Zhang, J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.068 · Cited by 155
Advances and applications of nanoparticles in cancer therapy
Huang, X., He, T., Liang, X., Xiang, Z., Liu, C., Zhou, S., Luo, R., Bai, L., Kou, X., Li, X., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.67 · Cited by 156
Yokoyama, M. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.06.002 · Cited by 152
Ke, X., Ng, V. W. L., Ono, R. J., Chan, J. M. W., Krishnamurthy, S., Wang, Y., Hedrick, J. L., & Yang, Y. Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.061 · Cited by 146
Ding, H., Sumer, B. D., Kessinger, C. W., Dong, Y., Huang, G., Boothman, D. A., & Gao, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.004 · Cited by 141
Naguib, Y. W., Rodriguez, B. L., Li, X., Hursting, S. D., Williams, R. O., & Cui, Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4006968 · Cited by 134
Challenges and opportunities in the advancement of nanomedicines
Wei, A., Mehtala, J. G., & Patri, A. K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.10.007 · Cited by 127
A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs
Shin, H.-C., Alani, A. W. G., Cho, H., Bae, Y., Kolesar, J. M., & Kwon, G. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2000549 · Cited by 126
Current role of nanoparticles in the treatment of lung cancer
Carrasco-Esteban, E., Domínguez-Rullán, J. A., Barrionuevo-Castillo, P., Pelari-Mici, L., Leaman, O., Sastre-Gallego, S., & López‐Campos, F. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202102.005 · Cited by 124
Fang, Y., Jiang, Y., Zou, Y., Meng, F., Zhang, J., Deng, C., Sun, H., & Zhong, Z. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.01.007 · Cited by 116
Duong, H. H. P., & Yung, L. L. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.017 · Cited by 116
An overview of polymeric nanomicelles in clinical trials and on the market
Zheng, X., Xie, J., Zhang, X., Sun, W., Zhao, H., Li, Y., & Wang, C. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.11.029 · Cited by 114
Graphene oxide stabilized by PLA–PEG copolymers for the controlled delivery of paclitaxel
Angelopoulou, A., Voulgari, E., Diamanti, E. K., Gournis, D., & Avgoustakis, K. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.022 · Cited by 110
Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery
Xu, C., Zhang, H., Sun, C., Liu, Y., Shen, S., Yang, X., Zhu, Y., & Wang, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.031 · Cited by 108
Immunological Risk of Injectable Drug Delivery Systems
Jiskoot, W., van Schie, R. M. F., Carstens, M. G., & Schellekens, H. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9855-9 · Cited by 98
Dogbey, D. M., Torres, V. E. S., Fajemisin, E. A., Mpondo, L., Ngwenya, T., Akinrinmade, O. A., Perriman, A. W., & Barth, S. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01362-3 · Cited by 105
Polymeric Materials for Theranostic Applications
Wang, Z., Niu, G., & Chen, X. S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1103-7 · Cited by 103
Nanomedicine Combats Drug Resistance in Lung Cancer
Zheng, X., Song, X.-H., Zhu, G., Pan, D., Li, H., Hu, J., Xiao, K., Gong, Q., Gu, Z., Luo, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308977 · Cited by 103
Çiftçi, F., Özarslan, A. C., Kantarci, İ. C., Yelkenci, A., Tavukçuoğlu, Ö., & Ghorbanpour, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010121 · Cited by 103
Lee, S.-W., Kim, Y.-M., Cho, C. H., Kim, Y. T., Kim, S. M., Hur, S. Y., Kim, J.-H., Kim, B.-G., Kim, S.-C., Ryu, H.-S., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2016.376 · Cited by 94
Self-citationClinical applications of nanomedicines in lung cancer treatment
Norouzi, M., & Hardy, P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.009 · Cited by 97
Garofalo, C., Capuano, G., Sottile, R., Tallerico, R., Adami, R., Reverchon, E., Carbone, E., Izzo, L., & Pappalardo, D. (2013) · Biomacromolecules · doi:10.1021/bm401812r · Cited by 96
Hasenstein, J. R., Shin, H.-C., Kasmerchak, K., Buehler, D., Kwon, G. S., & Kozak, K. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0987 · Cited by 83
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
Li, J., Zhu, L., & Kwok, H. F. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100904 · Cited by 94
Overcoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic
Houdaihed, L., Evans, J. C., & Allen, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00188 · Cited by 91
Qu, X., Zhou, D. F., Lu, J., Qin, D., Zhou, J. M., & Liu, H.-J. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.010 · Cited by 89
Ultrasound-mediated micellar drug delivery
Rapoport, N. Y. (2012) · International Journal of Hyperthermia · doi:10.3109/02656736.2012.665567 · Cited by 89
Maßgeschneiderte Nanopartikel für den Wirkstofftransport in der Krebstherapie
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie · doi:10.1002/ange.201403036 · Cited by 86
Yi, Y., Lin, G., Chen, S., Liu, J., Zhang, H., & Mi, P. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.10.004 · Cited by 86
NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells
Wang, X., Wang, Y., Chen, X., Wang, J., Zhang, X., & Zhang, Q. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.05.030 · Cited by 85
Bose, T., Latawiec, D., Mondal, P. P., & Mandal, S. (2014) · Journal of Nanoparticle Research · doi:10.1007/s11051-014-2527-7 · Cited by 85
Clinical developments of antitumor polymer therapeutics
Parveen, S., Arjmand, F., & Tabassum, S. (2019) · RSC Advances · doi:10.1039/c9ra04358f · Cited by 84
Disposition of Drugs in Block Copolymer Micelle Delivery Systems: From Discovery to Recovery
Aliabadi, H. M., Shahin, M., Brocks, D. R., & Lavasanifar, A. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847100-00001 · Cited by 83
Shi, M., Gu, A., Tu, H., Huang, C., Wang, H., Yu, Z., Wang, X., Cao, L., Shu, Y., Wang, H., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.479 · Cited by 82
Lee, J., Ahn, J., Park, S. H., Lim, H. Y., Kwon, J. H., Ahn, S., Song, C., Hong, J. H., Kim, C., & Ahn, H. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9757-7 · Cited by 80
Bisht, S., Feldmann, G., Koorstra, J.-B. M., Mullendore, M. E., Alvarez, H., Karikari, C. A., Rudek, M. A., Lee, C. K., Maitra, A., & Maitra, A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0476 · Cited by 77
Gawali, P., Saraswat, A. L., Bhide, S., Gupta, S., & Patel, K. R. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0257 · Cited by 75
Lu, J., Chuan, X., Zhang, H., Dai, W., Wang, X., Wang, X., & Zhang, Q. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.05.032 · Cited by 75
Multifunctional approaches utilizing polymeric micelles to circumvent multidrug resistant tumors
Kesharwani, S. S., Kaur, S., Tummala, H., & Sangamwar, A. T. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.10.022 · Cited by 74
Metadata
- Authors
- Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S.
- Affiliations
- Seoul National University (KR)
- Asan Medical Center (KR)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- Korea University Anam Hospital (KR)
- Samsung Medical Center (KR)
- Samyang Holdings (South Korea) (KR)
- Corresponding author
- Heo, D.S.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 18
- Issue
- 12
- Pages
- 2009-2014
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2155680971
- Cited by
- 356
- References
- 27
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 19 · 2023: 13 · 2022: 24 · 2021: 12 · 2020: 22 · 2019: 15 · 2018: 19 · 2017: 18 · 2016: 30 · 2015: 24 · 2014: 31 · 2013: 28 · 2012: 17
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4385 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- paclitaxel, polymeric micelles, cisplatin, non-small cell lung cancer, combination chemotherapy, first-line therapy, dose escalation, peripheral sensory neuropathy, neutropenia, hypersensitivity, anticancer activity
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Micelles, Middle Aged, Polymers, Treatment Outcome, Paclitaxel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.